Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by SM Tolaney
A Longitudinal Investigation of the Relationships Between Patient-Reported Symptoms and Survival Among Patients With HR+/HER2- Metastatic Breast Cancer (MBC) Treated With Abemaciclib in the Phase 2 Monarch 1 Trial
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
MONARCH 1, a Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR + /HER2 − Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Prolonged Survival of Patients Receiving Trastuzumab Beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)
Oncology Research and Treatment
Cancer Research
Oncology
Hematology
The Impacts of Inclusion in Clinical Trials on Outcomes Among Patients With Metastatic Breast Cancer (MBC)
PLoS ONE
Multidisciplinary
Everolimus-Based Therapy Versus Chemotherapy Among Patients With HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness From a Chart Review Study
International Journal of Breast Cancer
Cancer Research
Oncology
Pharmacology
Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Patient Reported Outcomes of Symptoms and Quality of Life Among Cancer Patients Treated With Palliative Pelvic Radiation: A Pilot Study
BMC Research Notes
Biochemistry
Medicine
Genetics
Molecular Biology
A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer
Clinical Cancer Research
Cancer Research
Oncology
Real-World Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
Scientific Reports
Multidisciplinary
Metastatic Presentations of Previously Treated Early Stage Breast Cancer Patients and Association With Survival
Clinical Breast Cancer
Cancer Research
Oncology
